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The aim of the present work was to take advantage of lecithin’s biocompatibility along with its physicochemical properties for the
preparation of lecithin-based nanocarriers for small interfering RNA (siRNA) delivery. Water lecithin dispersions were prepared
in diﬀerent conditions, loaded with siRNA at diﬀerent N/P ratios, and evaluated for loading capacity. The most appropriate ones
were then assayed for cytotoxicity and characterized in terms of particle size distribution, zeta potential, and morphology. Results
demonstrated that formulations prepared at pH 5.0 and 7.0 were able to load siRNA at broad N/P ratios, and cellular uptake assays
showed an eﬃcient delivery of oligos in MCF-7 human breast cancer cells; ﬂuorescent-labeled dsRNA mainly located next to its
target, near the nucleus of the cells. No signs of toxicity were observed for broad compositions of lecithin. The physicochemical
characterization of the siRNA-loaded dispersions exhibited particles of nanometric sizes and pH-dependant shapes, which make
them suitable for ex vivo and in vivo further evaluation.
1.Introduction
The silencing of genes by interference with RNA (iRNA)
is a natural biological process that implies the silencing of
genes with small fragments of RNA (siRNA) [1, 2]. siRNA
molecules can knockdown their cognate targets speciﬁcally
and eﬀectively based on direct homology-dependent post-
transcriptionalgenesilencing[3].AcommonfeatureofRNA
silencing is production of small (21–23 nucleotide) RNAs
(siRNA). Double-stranded RNA produced by transposons,
replicating viruses, or regulatory noncoding micro-RNAs
is recognized by the endonuclease Dicer and cleaved into
fragments called siRNA. A multienzyme complex, which
includes Argonaute 2 (AGO 2) and the RNA-induced silenc-
ing complex (RISC), binds to siRNA duplex and discards the
sense strand to form and activated complex containing the
antisense strand. The AGO2-RISC complex then targets an
mRNA strand sharing a complementary sequence and leads
to its degradation, shutting down protein expression [4].
After iRNA demonstration in mammalian cells in 2001,
it was quickly realized that this highly speciﬁc mechanism
of sequence-speciﬁc gene silencing might be harnessed to
develop a new class of drugs that interfere with disease-
causing or disease-promoting genes [5]. One of the most
important advantages of using siRNA is that, compared
to antisense oligonucleotides, siRNA is 10–100-fold more
potent for gene silencing [6].
To date, the production of eﬀective gene delivery vectors
is the bottleneck limiting the success of gene-based drugs in
clinical trials. The development of siRNA delivery systems
may progress faster than the design of DNA carriers. Indeed,
separation of small fragments of dsRNA from its carrier is2 Journal of Drug Delivery
easier than the delivery of a plasmid from the same carrier.
Furthermore, when siRNA is released into the cytoplasm,
as it has lower molecular weight than plasmid DNA, it
diﬀuses faster in the crowded cytosol. The target of siRNA
is located in the cytosol, rather than in the cell nucleus,
so a nuclear barrier does not exist for siRNA delivery
[7]. Moreover, several studies have demonstrated increased
eﬃciency of RNA transfection relative to DNA transfection
in nondividing cells [8] and in human primary melanocytes
[9].
The major limitations against the use of siRNA as a
therapeutic tool are its degradation by serum nucleases,
poor cellular uptake, and rapid renal clearance following
systemic administration. Although many siRNA carriers
have been reported for in vitro applications, these delivery
systems are usually inappropriate for in vivo use. Most of the
siRNA-based therapies that have entered into clinical trials
imply local delivery such as the intravitreal or intranasal
r o u t e s .H o w e v e r ,s y s t e m i cd e l i v e r yo fs i R N Af o ra n t i c a n c e r
therapies, for example, depends on the development of
eﬀective nanocarriers for siRNA systemic administration [6,
10–12].
The ideal in vivo delivery system for siRNA is expected to
provide robust gene silencing, be biocompatible, biodegrad-
able and nonimmunogenic, and bypass rapid hepatic or
renalclearance.Furthermore,anidealdeliverysystemshould
be able to target siRNA speciﬁcally into the tumour by
interacting with tumour-speciﬁc receptors. Nanocarriers
that are deﬁned as submicron (ranging from 1 to 1000nm)
oﬀer great advantages to fulﬁll these requirements [6].
Nanoparticles such as liposomes, micelles, emulsions,
and solid lipid nanoparticles have been used for siRNA
delivery. Cationic lipids have been traditionally the most
popular and widely used delivery systems. Liposomes are
uni- or multilamellar vehicles consisting of a phospholipid
bilayer with hydrophilic and/or aqueous inner compart-
ment [13]. DNA/cationic lipid (lipoplexes), DNA/cationic
polymer (polyplexes), and DNA/cationic polymer/cationic
lipid (lipopolyplexes) electrostatic complexes were proposed
as nonviral nucleic acids delivery systems [14]. Lipoplexes
containing siRNA resulted in acceptable in vitro transfection
eﬃciency. Nevertheless, and they have had limited success
for in vivo gene downregulation, they have also exhibited a
dose-dependent toxicity and a low colloidal stability under
physiological conditions with poor intracellular release
of the oligonucleotides. Cationic lipids can also activate
the complement system and cause their rapid clearance
by macrophages of the reticuloendothelial system [15].
Although cationic lipid-based delivery systems oﬀer some
advantagesasapotentialsiRNAdeliverysystem,potentialfor
lungandothertoxicitiesmayrequirealternativepreparations
for safety [16–18]. Therefore, careful selection of lipids and
formulation strategies may help reduce or eliminate toxicity
and potential adverse eﬀects [6].
One of the most important advances in the siRNA
delivery ﬁeld has been the development of neutral 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine- (DOPC-) based
nanoliposomes [19–22]. These nanoliposomes can deliver
siRNA in vivo into tumour cells 10- and 30-fold more
eﬀectively than cationic liposomes (DOTAP) and naked
siRNA, respectively [23]. However, the preparation tech-
nique involves the use of organic solvents and addition of
surfactants of limited biocompatibility.
Lecithin is a mixture of phospholipids with phos-
phatidylcholine(PC)asamaincomponent(upto98%w/w).
Egg or soy lecithin as well as puriﬁed phospholipids is used
for pharmaceutical purposes as components of liposomes,
mixed micelles, and submicron emulsions. Aqueous lecithin
dispersion ((WLD) water lecithin-dispersion) is a system
obtained by dispersing lecithin in water or in an isotonic
aqueous solution (e.g., mixture of glycerol and water)
with means of extensive mixing at temperature 40–60◦C
in order to obtain good hydration of lecithin. Neither
special manufacturing procedure nor additional lipids and
surfactants are used [24].
Cui et al. have proposed the use of lecithin for the
design of nucleic acid delivery systems; they have achieved
a signiﬁcant improvement in the stability of a previously
reported nanoparticle-based DNA delivery system using
the cationic tensioactive CTAB (Cetyltrimethylammonium
bromide). A plasmid was adsorbed onto the surface of the
lecithin nanoparticles and was successfully transfected to
cultured cells; however, this formulation resulted to be very
toxic [25].
The idea of the present work was to take advantage of
lecithin’s biocompatibility along with its physicochemical
properties for the preparation of water lecithin dispersions
using diﬀerent isotonic solutions; these dispersions would be
u s e dt h e na sn a n o c a r r i e r sf o rs i R N Ad e l i v e r y .E v a l u a t i o n s
of siRNA loading capacity were carried out so as to select
the most appropriate systems; these formulations were
then characterized through physicochemical parameters and
assayed for cytotoxicity and eﬃcient cellular uptake.
2.MaterialsandMethods
2.1. Materials. Commercially available RNAi reporter con-
trol and the transfection reagent Lipofectamine RNAiMAX
were obtained from Invitrogen (CA, USA). Soybean lecithin
(Phospholipon 90G, 90%w/w of phosphatidylcholine) was
purchased from Lipoid (Ludwigshafen, Germany). Highly
puriﬁed water was used (Millipore, Bedford, USA.). All
other reagents were of analytical grade and used without
further puriﬁcation. MCF-7 human breast cancer cell line
was obtained from the American Type Culture Collection
(ATCC) (Rockville, MD, USA). Cells were maintained in
Dulbecco’s minimum essential medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 50µg/mL gen-
tamycine (Invitrogen, Argentina), and 2mM L-glutamine
(Invitrogen, Argentina). Cells were cultured in 75cm2 cul-
ture ﬂasks at 37◦C in a humidiﬁed atmosphere of 5% CO2.
2.2. Preparation of Water-Lecithin Dispersions (WLDs). Dis-
persions of soybean lecithin from 25mM to 100mM phos-
phatidylcholine (PC) in diﬀerent diluents (distilled water,
isotonic solution of glycerol 2.76%w/w, 66mM isotonic
phosphate buﬀer pH 7.0, and 50mM isotonic acetate buﬀerJournal of Drug Delivery 3
pH 5.0) were prepared. Buﬀers were isotonized by adding
sodium chloride when necessary according to S¨ orensen and
White-Vincent methods. Lecithin was ﬁrst dispersed in the
appropriate diluent with means of extensive mixing at 60◦C
by use of a thermostated magnetic stirrer in order to obtain
good hydratation. Next, the dispersion was stirred for 2
minutes at the same temperature with a high-shear mixer
(Ultra-Turrax T25 basic, IKA Werke, Staufen, Germany) at
13,000rpm and sonicated at 20kHz for 10 minutes [26]. It
was then sterilized by autoclaving (121◦C, 15min) so as to
evaluate changes in macroscopic aspect and cytotoxicity in
comparison to nonsterilized dispersion.
2.3. Gel Retardation Assay. Lecithin dispersed in diﬀerent
concentrations in water, glycerol, pH 7.0, and pH 5.0 buﬀers
was combined with 10pmol of RNAi and allowed to stay
at room temperature for 20 minutes for dsRNA binding.
The eﬀect of the diluents on siRNA loading was investigated
using electrophoresis on 1% agarose gel with Tris-acetate
(TAE) running buﬀer at 100V for 30min. siRNA was
visualized with ethidium bromide (0.5µg/mL). To analyze
the inﬂuence of the N/P ratio used (N = nitrogen from
phosphatidylcholine groups; P = siRNA phosphate groups)
in the loading capacity of the systems, a series of diﬀerent
phosphatidylcholine to siRNA weight ratios was prepared
and incubated in order to obtain ﬁnal N/P ratios ranging
from 1 to 8000.
2.4. Cytotoxicity Assay. Cells were seeded in clear 96-well
plates (Corning Costar, Fisher Scientiﬁc, USA) at a density of
10,000 cells/well. After 24h, 5µL of the lecithin dispersions
were added in 200µL of medium. Cells were incubated at
37◦C for 48h in a 5% CO2 atmosphere. Then medium was
changed for fresh medium, and the WST (water soluble
tetrazolium salts) solution was added and manipulated
according to the manufacturer’s instructions. Cell number
was evaluated using the CellTiter 96 aqueous nonradioactive
cell proliferation assay (Promega). Triplicates were run for
each treatment. Values were expressed in terms of percent of
untreated control cells set as 100%.
2.5. Physical Characterization of the Size and Surface Charge
of the Particles. The particle size of the resulting particles,
bothsiRNAloadedandunloaded,wasdeterminedbyphoton
correlation spectroscopy (PCS) using a Zetasizer (Malvern
Nano ZS, Malvern Instruments Ltd., UK). Measurements
were performed at 25◦C, collecting backscattered light at
173◦. Each run underwent 12 subruns. The evaluations
applied values of 0.89cP and of 1.33 for the viscosity
and the refractive index of the solutions, respectively. The
electrophoretic mobility and zeta potential of the samples
weremeasuredbythesameinstrumentandthezetapotential
values were calculated according to Smoluchowski equation.
Prior to analysis, siRNA-loaded particles were collected by
ultracentrifugation (Eppendorf centrifuge 5415R, Hamburg,
Germany) at 13,000×g for 10min. The supernatants were
discarded, and nanoparticles were resuspended in distilled
water.
2.6. Morphology Determined by Transmission Electron Micro-
scopy (TEM) and Scanning Electron Microscopy (SEM). The
size and morphology of the particles were observed using
a transmission electron microscope (Zeiss 10-C TEM) in
the University of Buenos Aires Electron Microscope Facility
(LANAIS, Institute of Cellular Biology) and a scanning
electronmicroscopewithﬁeldemission gun (ZeissSupra40)
in the Advanced Microscopy Center (CMA) of the University
of Buenos Aires. Lecithin-based dispersions alone as well as
loaded with siRNA—incubated for 20 minutes at N/P =
8000—were analyzed.
For TEM analysis, one drop of sample was deposited on
a carbon-coated 200-mesh copper specimen grid and left to
stand for 1.5min, and all excess ﬂuid was removed with ﬁlter
paper. The grid was then stained with one drop of 1% uranyl
acetate solution (0.2µm ﬁltrated) for 30s, and all excess of
uranyl acetate was again removed with ﬁlter paper. The grid
was allowed to dry at room temperature in a dust-free place
before being examined. A negative uranyl acetate-stained
blank was also performed. For SEM analysis, one drop of
sample was deposited and dried on a silicon wafer and then
coated with gold using an ion sputter.
2.7. Intracellular Delivery of Fluorescent-Labeled Oligo.
siRNA uptake was evaluated by transfection of the MCF-
7 cells with a red-ﬂuorescent-labeled double-stranded RNA
(dsRNA) (BLOCK-iT Alexa Fluor Red Fluorescent Oligo,
Invitrogen). Following manufacturer’s recommendations,
reverse transfection in medium with serum was performed,
though direct transfection was ﬁrst evaluated but without
success. To evaluate cellular uptake, ﬂuorescent dsRNA and
the lecithin dispersions were mixed and incubated 20 min-
utes; for control experiments, Lipofectamine was also mixed
with the dsRNA and assayed in parallel. The dsRNA:lecithin
complexes, the control dsRNA:Lipofectamine control com-
plex, and dsRNA alone were then added to 24-well plates
prior to the addition of 2 × 105 MCF-7 cells per well. Cells
were incubated 18 hours at 37◦Ci naC O 2 incubator, being
then washed and ﬁxed and the ﬂuorescence signal detected
using ﬂuorescence microscopy.
2.8. Stability of the Nanoparticles. The lecithin-based disper-
sions prepared as previously described were sealed into glass
vials and stored at room temperature in the dark for one
month. The size of the particles was measured by PCS on day
0 and after one month of storage.
2.9. Statistical Analyses. Statistical analyses were carried out
using one-way analysis of variance (ANOVA) in GraphPad
InStat 3.01 for Windows. For cytotoxicity data evaluation,
ANOVA was followed by the Dunnett multiple comparisons
test procedure against control. A P value of ≤0.05 (two
tailed) was considered to be statistically signiﬁcant.
3. Results and Discussion
In order to evaluate the siRNA loading capacity of the
formulations, the appropriate diluent was ﬁrst selected. For4 Journal of Drug Delivery
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Figure 1: Gel retardation assay of formulations in diﬀerent media
(a: water, b: glycerol 2.76%w/w, c: pH 5.0 buﬀer, d: pH 7.0
buﬀer). Control assay involved siRNA alone (−)o ri sa s s o c i a t e dt o
Lipofectamine (+). (Upper bands: bound siRNA).
this purpose, aqueous soybean lecithin dispersions were
preparedindiﬀerentmedia,andbindingbetweensiRNAand
dispersed lecithin was analyzed by agarose gel retardation
assay. As it is shown in Figure 1, lecithin bound the
oligonucleotidewhendispersedinpH5.0andpH7.0buﬀers,
but was unable to assemble when dispersed in water or
glycerol. The same results were obtained for all the diﬀerent
lecithin concentrations tested.
Being unsuitable diluents disregarded, dispersions in pH
5.0 and pH 7.0 buﬀers were then loaded with siRNA at
diﬀerent N/P ratios and analyzed by means of the same
assay. Results demonstrated that lecithin is assembled with
siRNA in a broad range of N/P ratios, especially above 1000
(Figure 2). Meanwhile, it is to remark that only lecithin
dispersedinpH5.0buﬀerwasabletoatleastweaklyassociate
at much lower ratios, whereas at pH 7.0, binding was not
observed below N/P 100. This fact can be related to the
higher proportion of the positively charged form of the
phosphocholine polar head at lower pH values, supported
by the zeta potential results which are later presented and
discussed.
In order to prove the safety of the carrier systems
proposed, cytotoxicity of WLD in pH 5.0 and pH 7.0
buﬀers was then analyzed. The rate of viability was assessed
by means of the water soluble tetrazolium salts (WST)
reduction assay. A broad range of lecithin concentrations
weretested,butnoneofthemshowedcytotoxicity(Figure 3),
which is in agreement with previous ﬁndings from other
authors [27, 28]. No signiﬁcant diﬀerences in cytotoxicity
and macroscopic aspect were observed between autoclaved
and nonsterilized samples (data not shown).
The sizes of the resulting lecithin-based particles in
the selected WLDs were determined by photon correlation
spectroscopy (PCS). As shown in Figure 4, particles in the
range of 180–250nm were readily obtained for the diﬀerent
systems. As expected, the zeta potential of the particles was
positive when using pH 5.0 buﬀer as diluent and negative
when using pH 7.0 buﬀer. This fact can be related to the
changes in proportion of the diﬀerently charged forms of the
zwitterionic phosphocholine polar head of the amphiphile
within the selected pH range and the conformational
organization the molecules acquire as a result.
Measurements of the systems after a 30-day storage
period could not be properly carried out, as the WLDs
prepared showed ﬂocculation. Though, it is to remark
that redispersion and macroscopic reconstitution was easily
achieved by gentle shaking.
WLDs were then loaded with siRNA at diﬀerent N/P
ratios and evaluated for size and zeta potential as well
(Table 1). The phosphatidylcholine concentration selected
for the assay was 25mM due to the macroscopic instability
showed by the most concentrated systems. It can be observed
that as the N/P ratios decrease (more siRNA added), particle
sizes tend to slightly decrease as well. Probably, this is
due to the change in the electrostatic interactions present
in the polar head of phosphatidylcholine when siRNA is
added, allowing a structural reorganization and formation of
smaller particles.
Since in Figure 4 unloaded dispersions at pH 5.0 showed
positive values of zeta potential, there is a marked contribu-
tion oftheloadeddsRNA,whichturnsthesystemtonegative
values. This contribution is much slighter in the case of
the dispersions at pH 7.0, where already negatively-charged
unloaded dispersions tend to slightly decrease their zeta
potential upon siRNA addition. In both cases, there is a
slight tendency within formulations of the same pH to more
negative values as the N/P ratio decreases, which could
indicate that location of the oligonucleotide is at least in part
on the surface of the particles.
TEM and SEM images of the particles are presented in
Figures 5 and 6, respectively. The sizes derived from the
micrographs tend to be smaller than that measured when
using the particle sizer. This is understandable because the
photon correlation spectroscopic particle sizer determines
the size of the particles by measuring the movement of the
particles due to Brownian motion. Therefore, the particle
size determined using the particles sizer was in fact the size
of the particles with their surrounding aqueous boundary
layer, which moved together with the particles. In contrast,
the particle size derived from the micrograph was the size of
the particles alone [25].
WLD regulated at pH 5.0 containing 25mM phos-
phatidylcholine exhibited particles of nanometric size and
irregular shape (Figure 5(a)); when loaded with siRNA, the
particles changed to a spherical shape of a smaller diameter
(Figure 5(b)). Probably, this change in shape is due to the
change in the electrostatic interactions present in the polar
head of phosphatidylcholine when the oligonucleotide is
added, allowing a structural reorganization. While at pH 5.0,
small, spherical, isolated particles are presented, at pH 7.0
more elongated, locally cylindrical structures are observed
(Figures 5(c) and 5(d)).
In our work, the presence of salts like NaCl and sodium
acetate collaborates to increase the ionic strength of the
medium. It is well known that the higher the ionic strength
of the medium, the lower the critical micelle concentration
(CMC) as well as the size of the structures. Walter and
colleaguesstudied the vesicle-to-micelle transition process in
buﬀers with 0–4M sodium chloride, sucrose, and urea and
concluded that the CMC decreased in high salt and sucroseJournal of Drug Delivery 5
1000 2000 4000 8000 − + 148 16 100 − +
(a)
1 4 16 100 + − 28 1000 2000 4000 8000 − +
(b)
Figure 2: Gel retardation assay of selected WLDs in (a) pH 5.0 and (b) pH 7.0 buﬀers at diﬀerent N/P ratios. Control assay involved siRNA
alone (−) or associated to Lipofectamine (+). (Upper bands: bound siRNA).
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Figure 3: Cytotoxicity assay in MCF-7 cells of WLDs (25mM,
50mM, and 100mM phosphatidylcholine) prepared in pH 5.0
and pH 7.0 buﬀers. No signiﬁcant diﬀerences in cytotoxicity
were observed for the diﬀerent formulations when compared with
untreated control cells (Dunnet t test; P>0.05). Data shown are
mean ± SD (n = 3).
buﬀers [29]. Moreover, it has been reported by Huang that
in aqueous C8-lecithin solution, chloride salts ﬁrst slightly
raise the CMC and then decrease it, while the ionic strength
increases [30]. This may contribute to the quick and easy
formation of deﬁned particles after siRNA loading and also
determine their nanometric sizes.
Recently, Barichello et al. demonstrated that a proper
siRNA lipoplex preparation procedure is strongly related
to both the eﬃciency of cellular uptake and the gene-
knockdown eﬃciency of siRNA. He suggested that, the
results obtained using agitation during lipoplex preparation
may have implications for designing more eﬃcient and
successful siRNA delivery systems [31]. Silvander et al.
prepared small unilamellar vesicles by ultrasonic irradiation
of samples containing about 25mg of lecithin in 5mL pH
7.4 buﬀer (10mM Tris-HCl containing 150mM NaCl). The
samplesweresonicatedfor1hourandthereafterdilutedwith
buﬀer to the desired concentration [32]. In our work, we
employ additional stirring by a high-shear mixer previous to
sonication, and buﬀers of the same but also lower pH.
Silvander using diﬀerent characterization methods con-
cluded that vesicles were formed. After that they added
diﬀerent anionic tensioactives and demonstrated the transi-
tion from vesicles to micelles through diﬀerent intermediate
states. As revealed by cryo-TEM micrographs, micelles of
various types and shapes may form during solubilization
of lecithin vesicles by alkyl sulfate surfactants [32]. All the
evaluated systems have shown globular micelles at high
surfactant concentration, and for instance, we found this
shape for the siRNA-loaded nanoparticles prepared at pH
5.0. Therefore, we cannot discard this transition to micelles,
or at least the feasibility of coexistence between vesicles and
micelles.
The phosphocholine polar head is zwitterionic at pH
between 3 and 11; this means that in this pH range the
phosphate group of the polar head has a net negative charge
of electrons, and the choline group has an equal positive
charge with a spatial separation. In aqueous solution, 3–5
water molecules are bound to the phosphate group, while
none is bound to the choline group. When salts are added to
the solution, anions are attracted by the choline group, and
cations are bound to the phosphate group [30, 33]. It can
be supposed, then, that nanometric spherical particles are
formed at pH 5.0 because of the interaction between siRNA
and PC, more speciﬁcally because of the interaction between
the positively charged amine group of phosphatidylcholine
and the phosphate groups of siRNA. Meanwhile, at pH6 Journal of Drug Delivery
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Figure 4: Eﬀect of pH and concentration on the particle size and zeta potential of the lecithin nanoparticles. Dispersions of diﬀerent
concentrations of phosphatidylcholine (PC) in pH 5.0 buﬀer (a) and pH 7.0 buﬀer (b) were prepared and analyzed by dynamic light
scattering (DLS). The size and zeta potential of the particles were measured and reported as mean ± SD (n = 4).
Table 1: Particle size and zeta potential of the siRNA-loaded lecithin nanoparticles, reported as mean ± SD (n = 4).
Formulation N/P ratio Particle size (d.nm) ± SD PdI Z-pot (mV) ± SD
pH 5.0
8000 364,9 ± 35,4 0,452 −35,5 ± 2,7
4000 384,5 ± 51,5 0,280 −54,4 ± 5,2
2000 303,2 ± 1,4 0,185 −59,1 ± 3,1
1000 252,5 ± 19,8 0,263 −59,7 ± 2,2
100 196,9 ± 14,1 0,398 ∗
pH 7.0
8000 371,5 ± 36,3 0,463 −41,3 ± 1,9
4000 375,5 ± 27,1 0,484 −58,4 ± 3,4
2000 343,4 ± 25,7 0,470 −61,4 ± 2,6
1000 328,2 ± 61,9 0,448 −63,1 ± 3,0
100 271,5 ± 28,2 0,463 ∗
∗Unable to determine, low signal-to-noise ratio.
7.0, these interactions could be less relevant as a result of
the decrease in the proportion of the positively charged
forms of the zwitterionic phosphocholine polar head of
the amphiphile, which is in agreement with the z potential
values obtained. As a consequence, diﬀerent conformational
organization of molecules is acquired.
Proper internalization of the delivered siRNA was tested
on MCF-7 cells transfected with the vehicle. However, it
must be taken into account that the ﬁnal silencing eﬀect
depends also on the endolysosomal escape and the eﬃcient
incorporation of siRNA to the RNA-induced silencing
machinery. To analyze the cellular uptake of oligos delivered,
a red-ﬂuorescent-labeled dsRNA was transfected to MCF-7
cells which were then analyzed by ﬂuorescence microscopy.
Control experiments were performed in parallel: BLOCK-
iT Alexa Fluor Red Fluorescent Oligo was incubated alone
with MCF-7 to assess unspeciﬁc ﬂuorescence, and it was also
delivered with commercially available transfection medium
recommended for dsRNA transfection to assess eﬃcient
delivery of the ﬂuorescent oligo. As it can be observed in
Figure 7, both lecithin dispersions at pH 5.0 and pH 7.0 are
able to eﬃciently deliver oligos in MCF-7 cells. FluorescentJournal of Drug Delivery 7
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Figure 5: Transmission electron micrographs of the lecithin-based nanoparticles. Lecithin-based dispersions containing 25mM
phosphatidylcholine, alone in pH 5.0 (a) and pH 7.0 (c) buﬀers, are shown. The same dispersions were then loaded with siRNA at N/P
= 8000 and incubated, and the siRNA-loaded nanoparticles were observed (b and d, resp.).
(a) (b)
Figure 6: Scanning electron micrographs of the siRNA-loaded lecithin-based nanoparticles in pH 5.0 (a) and pH 7.0 (b) buﬀers.
siRNA mainly located in the cytoplasm of the cells near the
nucleus (Figures 7(c) and 7(d)). In contrast, ﬂuorescently
labeled naked siRNA was not detected by ﬂuorescence
microscopy (Figure 7(b)) neither within cells nor in the
extracellular medium, suggesting that siRNA is degraded or
removed by washing the cells when the incubation period is
ﬁnished.
4. Conclusions
In the present work, a siRNA lecithin-based delivery system
capable to improve the disadvantages that nonviral carriers
normally present, like poor cellular uptake or high cytotoxic-
ity, was readily obtained. It was not necessary to add other
components like cationic lipids or cationic surfactants, of8 Journal of Drug Delivery
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Figure 7: Fluo-siRNA uptake by MCF-7 cells transfected with lecithin dispersions in pH 5.0 and pH 7.0 buﬀers. Control
dsRNA:Lipofectamine (a), dsRNA alone (b), dsRNA:lecithin 25mM pH 5.0 (c), and dsRNA:lecithin 25mM pH 7.0 (d) at N/P 8000 were
incubated with the MCF-7 cells for 18h. Afterwards, cells were washed and ﬁxed, and ﬂuorescent signal was visualized by microscopy.
recognized toxicity, so as to improve siRNA loading capacity.
Inthiscase,theeﬃciencyinloadingwasreachedbymeansof
theoptimizationofthecriticalparametersintheelaboration,
such as pH and ionic strength. It was proposed that in the
case of nanoparticles obtained at lower pH, an important
electrostatic interaction between the oligonucleotide and the
positively charged head of the amphiphile is responsible for
the formation of isolated spherical particles, while at higher
pH, the interactions between charged groups of lecithin and
siRNA are less relevant.
When assessed in parallel with the commercial transfec-
tion reagent Lipofectamine, lecithin dispersions at pH 5.0
and pH 7.0 were both able to eﬃciently deliver oligos in
MCF-7 cells, in contrast to naked siRNA. Moreover, ﬂuores-
cent siRNA mainly located near its target, surrounding the
nucleus of the cells.
Neither other components like lipids for cell transfection
nor molecular modiﬁcations were necessary. If the absence
of toxicity and the signiﬁcant cellular uptake exhibited are
considered along with the ease of preparation, critical issues
for the rest of nanocarriers that have been proposed for
siRNA delivery, the present oligo delivery system represents a
promising one for further investigation.
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